Subject: MediSieve Updates

INSIDE THIS NEWSLETTER

  • The Telegraph Issue
  • BBSRC Innovator of the Year Award 
  • International Conferences 
  • Shareholder Visit
  • Flow Cytometer 
  • RSC Emerging Technologies Competition 
  • Meet our employee
MediSieve is Growing 
From an idea to steady growth 
Over this year MediSieve has gone through a series of exciting changes. We were granted several prestigious awards and presented at a number of major industry events to network with potential partners and investors. We have grown from a five-people start-up into a diverse team of 11 full-time employees. Three associate biochemists and a senior immunologist joined the technical team, working together to develop, test, and validate our magnetic particle products, focused on Sepsis. A QA/RA Analyst and Marketing Analyst have also joined to support MediSieve's push towards commercial success. 
MediSieve in The Telegraph
MediSieve was featured in this week’s Sunday issue of The Telegraph. Our CEO George Frodsham had a chance to talk about our revolutionary technology and his view on the company’s further development. This was a great opportunity to let more people learn about us and about our work.
Read the article here:
https://www.telegraph.co.uk/science/2019/11/10/blood-cleaning-treatment-pulls-disease-body-using-magnets-ready/

BBSRC Innovator of the Year
Dr George Frodsham, our founder and CEO, has won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019. The award was presented by Chris Skidmore MP, Minister of State for Universities, Science, Research and Innovation at an awards ceremony in the Science Museum, London.
Read more: https://www.medisieve.com/Latest-News/DNNArticle-Detail-View/ArticleId/7822/MediSieve-CEO-Winner-of-BBSRC-Innovator-of-the-Year-Award-1

MediSieve Attends International Conferences
Over summer we have attended several international conferences, including Biopharm America in Boston and BIO 2019, held in Philadelphia. Our CEO George had a chance to make connections with leading pharmaceutical and medical equipment companies, such as Baxter and AstraZeneca. The attendance of international conferences not only broadens our network and knowledge, but also provide us with new partnership opportunities.  
Shareholders Event
In September, we invited our shareholders to visit our facilities in the Translation and Innovation Hub in White City. The team updated investors on our current development stage and future plans, gave tours around the office and laboratory, and demonstrated our latest prototypes, allowing shareholders to meet the new team and see MediSieve devices in action. And all attendees walked away with a free MediSieve fridge magnet!
Follow us for more company insights: https://twitter.com/MediSieve

New Flow Cytometer
We have recently expanded our lab equipment with the purchase of a new flow cytometer. Flow cytometry provides the tools to evaluate how our devices interact with the cells of the immune system, with pathogens, and most importantly, with blood. Additionally, multiple parameters can be tested simultaneously, improving experimental efficiency and reducing product development time and cost. Having in-house capabilities give us a high degree of control and flexibility and reduces our reliance on external facilities with limited capabilities.
2019 Emerging Technologies Competition Finalist
We were shortlisted for the final round of 2019 Emerging Technology Competition, run by the Royal Society of Chemistry. Our CTO Cristina Blanco-Andujar got a chance to showcase our technology to a panel of judges and live audience during the final on 28 October 2019 at the Chemistry Means Business event.
Read more: https://www.rsc.org/competitions/emerging-technologies/shortlisted-entries-2019/#health

MediSieve Faces 
MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:
Silvia Prelez Alcaida
Associate Biochemist 
Nationality: Spanish/Italian
Joined: March 2019

What are your responsibilities within MediSieve?
- My responsibilities are focused on product development. One of my main duties is to assess the biocompatibility of our device, for example by measuring the haemolytic properties of the MediSieve particles following a standard protocol.

What originally drew you to MediSieve?
- I was very interested in the innovative concept of magnetic blood filtration to treat some of the deadliest blood-borne diseases in today’s society. Furthermore, joining the team at an early growth phase really motivated me as I feel my work can have a greater impact and influence on the success of the company.

What do you like most about working here?
- I really enjoy the atmosphere. As we are still a relatively small team, everybody is very approachable, and communication is very easy. I also feel this helps me have a more active role in the company, allowing me to learn new skills every day.

"Imagine a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream."
You may unsubscribe or change your contact details at any time.